We previously reported that the Fourth Circuit, via a 2-1 decision in United States ex rel. Sheldon v. Allergan Sales, LLC, 24 F.4th 340 (4th Cir. 2022), affirmed the dismissal of a False Claims Act (“FCA”) qui tam lawsuit...more
A few weeks ago, the U.S. Court of Appeals for the Fourth Circuit answered a critical inquiry in the False Claims Act (“FCA”) context: does a defendant violate the FCA when it’s reading of the regulation is objectionably...more
3/10/2022
/ Appellate Courts ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Justice (DOJ) ,
Dissenting Opinions ,
Fair Credit Reporting Act (FCRA) ,
False Claims Act (FCA) ,
Manufacturers ,
Medicaid ,
Medicaid Drug Rebate Program ,
Omnicare ,
Qui Tam ,
Safeco